CYTOGEN PROSTASCINT INITIAL USE WILL BE RESTRICTED TO SITES CERTIFIED BY ACNP; SCAN FOR METASTATIC PROSTATE CANCER IS COMPLEMENTARY TO OTHER TESTS
This article was originally published in The Gray Sheet
Executive Summary
Cytogen plans to restrict initial availability of its prostate cancer imaging agent ProstaScint (capromab pendetide) to sites certified by the American College of Nuclear Physicians. "We don't think it is appropriate for sites to use this product without training," Cytogen VP-Medical Affairs Robert Maguire, MD, told FDA's Medical Imaging Drugs Advisory Committee July 22. Cytogen will offer a "Partners in Excellence" training program for use of ProstaScint, he added.